Kurma Partners closed its fourth and largest venture fund at €215 million, targeting investments in companies pursuing disruptive therapeutic solutions. The fund builds on Kurma’s track record, which includes exits tied to acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. Fund size and stated strategy suggest an emphasis on earlier-stage bets with room for platform differentiation, as Kurma seeks to deploy capital across new therapeutic modalities and development pathways. For limited partners and startups, the close signals continued institutional commitment to venture-backed healthcare innovation even as technical standards for de-risking tighten.